Noticias de ARDX_US
Noticias del mercado
Últimas noticias sobre ARDX_US — 546 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
NEW YORK CITY, NY / ACCESS Newswire / October 1, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors ...
NEW YORK CITY, NY / ACCESS Newswire / October 1, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson alienta a los inversores que sufrieron pérdidas en Ardelyx a contactarlo directamente para discutir sus opciones
/PRNewswire/ -- SueWallSt reminds purchasers of Ardelyx, Inc. (NASDAQ: ARDX) securities that a securities class action is pending on behalf of shareholders who...
NEW YORK CITY, NY / ACCESS Newswire / September 30, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of ...
NEW YORK CITY, NY / ACCESS Newswire / September 30, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that ...
Ardelyx stock fell 17.86% to $4.00 after reporting Q2 2026 results below consensus estimates. Full-year 2026 IBSRELA revenue guidance was cut to $350-$370 million from $410-$430 million. The company withdrew its long-term $750 million revenue target for XPHOZAH while maintaining near-term guidance. Q2 product revenue rose 31% YoY to $118.1 million, driven by 33% growth in IBSRELA sales. Levi & Korsinsky, LLP announced an investigation into potential securities violations regarding disclosure of payer headwinds.
NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors ...
Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc....
/PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Ardelyx, Inc. (NASDAQ: ARDX) of a pending securities class action. Class Period: January 13, 2025...
El director ejecutivo Mike Raab fue nombrado director ejecutivo del año del fabricante de ciencias biológicas, mientras que el equipo de marketing de IBSRELA obtuvo la plata en la gala del 29 de septiembre en la ciudad de Nueva York.
NEW YORK CITY, NY / ACCESS Newswire / September 30, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of ...
Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year
NEW YORK CITY, NY / ACCESS Newswire / September 30, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of ...
Recognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the YearWALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that it received multiple honors at the 2026 PM360 Trailblazer Awards, recognizing the company, its leadership, and the work of
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK CITY, NY / ACCESS Newswire / September 29, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of ...
Página 9 de 28